Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · September 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05873686). This is a study registration, not published results. Lead sponsor: Nuvectis Pharma, Inc.. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 140 participants (ESTIMATED). Conditions: Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma, Non-Small Cell Squamous Lung Cancer, Non-small Cell Lung Adenocarcinoma. Interventions: DRUG: NXP900. Primary outcome measures: Number of patients with treatment related adverse events and/or clinical laboratory abnormalities , Up to 30 days post treatment; Part A: Number of patients who experience Dose Limiting Toxicities (DLT) as defined in the protocol , Day 28; Part B: Objective response rate (ORR) , Up to 24 months; Part B: Duration of Response (DoR) , Up to 24 months; Part B: Disease Control Rate (DCR) , Up to 24 months. Brief summary: This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.